UA021 / Usynova - LARVOL DELTA

The application for implied clinical trial approval of Yusen Jianheng Biopharmaceutical (Shanghai) Co., Ltd. was accepted [Google translation] (163.com) - "On April 15, according to the official website of CDE, Yousen Jianheng Biotechnology (Shanghai) Co., Ltd. jointly applied for the drug 'UA021 Capsule' and obtained implicit clinical trial approval, acceptance number CXHB2500022. Public information shows that the indications of the drug 'UA021 Capsules' are: This product is intended for the treatment of psoriasis."

New trial • Psoriasis